Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19 SEK | -1.35% | -2.36% | +22.90% |
05-08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
04-17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.90% | 61.23M | |
+7.22% | 72.81B | |
+14.11% | 9.13B | |
-11.75% | 5.13B | |
+59.61% | 4.99B | |
+2.62% | 3.9B | |
-17.54% | 2.48B | |
+21.35% | 2.42B | |
-27.82% | 2.32B | |
+25.13% | 2.17B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- US Court Confirms Validity of Orexo's Patents for Opioid Use Treatment Tablets